ResearchPod Summary
Standard first-line treatment for HER2-positive advanced gastroesophageal adenocarcinoma typically involves platinum-based chemotherapy combined with the monoclonal antibody trastuzumab. However, clinical outcomes remain limited. This phase 3, open-label, randomized trial (HERIZON-GEA-01) evaluated whether zanidatamab—a bispecific antibody that binds to two distinct domains of the HER2 receptor—could offer superior efficacy when added to chemotherapy, compared to the current standard of trastuzumab plus chemotherapy. Researchers also tested whether adding the PD-1 inhibitor tislelizumab to the zanidatamab regimen provided further benefit. The trial enrolled 914 patients across 33 countries, comparing three arms: zanidatamab-tislelizumab-chemotherapy, zanidatamab-chemotherapy, and the control arm of trastuzumab-chemotherapy.
At a median follow-up of 25.9 months, both zanidatamab-based regimens showed significantly longer progression-free survival (median 12.4 months for both) compared to the trastuzumab-chemotherapy control (median 8.1 months). When examining overall survival, the triple-therapy regimen (zanidatamab-tislelizumab-chemotherapy) was superior to the control (median 26.4 months vs. 19.2 months). In the interim analysis, the zanidatamab-chemotherapy group (without tislelizumab) demonstrated a median overall survival of 24.4 months, but this did not meet the prespecified threshold for statistical significance (P=0.06).
The safety profile was consistent with the known toxicities of the agents involved. Diarrhea was the most common high-grade adverse event, appearing more frequently in the zanidatamab-containing groups (up to 24.8% for grade 3+) than in the trastuzumab group (12.9%). Prophylactic measures for infusion reactions and diarrhea were implemented, which helped manage the clinical burden. While these findings position zanidatamab as a potent new option, clinicians should monitor for higher rates of gastrointestinal events. These results suggest that zanidatamab may eventually displace trastuzumab as a cornerstone of first-line therapy for this specific patient population.
Sam: A new antibody combination helped patients with advanced stomach and related cancers live longer. But the trial compared it with an older treatment, leaving a crucial question about current care unanswered.
Alex: So there is a survival gain, but also a gap between the experiment and the decision clinicians face. Whose study are we discussing?
Sam: It is an international, randomized phase three trial by Kohei Shitara, Lin Shen, and colleagues, published in the New England Journal of Medicine. It concerns previously untreated patients whose advanced cancers carry a particular treatment target.
Alex: That makes it relevant to researchers developing targeted treatments, not just those treating these cancers. What should we listen for?
Sam: Whether a different way of targeting the cancer improves outcomes, and what adding immunotherapy contributes. We will follow the biological idea, the randomized evidence, and the comparison this trial cannot resolve.
Alex: Start with the patients. What makes these cancers candidates for an antibody treatment?
Sam: The cancers arose in the stomach, the junction with the esophagus, or the esophagus itself. They were adenocarcinomas, cancers arising from glandular cells. All tested positive for human epidermal growth factor receptor two, usually called HER2, a receptor on the cell surface.
Alex: And the prior approach already targeted that receptor. What was left to improve?
Sam: For more than a decade, first-line treatment was the HER2-targeted antibody trastuzumab plus platinum-based chemotherapy. More recently, adding pembrolizumab, an immunotherapy, prolonged survival in patients selected by an immune-related tumor marker. The authors say outcomes nevertheless remain modest.
Alex: So the new ingredient is not simply targeting HER2. What does the replacement antibody do differently?
Sam: Zanidatamab binds two different locations on HER2, rather than the single location bound by trastuzumab. This lets it crosslink neighboring receptors into clusters. In preclinical studies, that promoted receptor removal and degradation, reduced downstream signaling, and recruited immune-mediated killing.
AI-generated third-party summary by ResearchPod. Not official content or an endorsement by the paper authors or affiliated organizations.
Alex: That offers a biological reason to try a replacement. But those mechanisms do not themselves show that patients live longer.
Sam: They are the rationale, not the clinical answer. Earlier phase two studies found encouraging activity with zanidatamab and chemotherapy, both with and without immunotherapy. Those outcomes compared favorably with historical treatments; this trial supplied a randomized comparison.
Alex: Before we get to that comparison, why add a separate immunotherapy if the antibody already recruits immune activity?
Sam: The added drug is tislelizumab. It blocks programmed death one, or PD-1, an immune checkpoint. The hypothesis was that combining this blockade with zanidatamab’s immune effects would further strengthen the response against the tumor.
Alex: That gives the study two related questions: whether replacing the HER2 antibody helps, and whether the immunotherapy-containing combination helps. How did they organize the test?
Sam: They randomly assigned 914 patients across an international network of hospitals. Everyone was assigned chemotherapy. One group received trastuzumab, another zanidatamab, and another zanidatamab together with tislelizumab.
Alex: With a targeted treatment, misclassifying the target could muddy the result. How did they establish that patients belonged in this population?
Sam: A central laboratory confirmed HER2 positivity before enrollment. Patients had unresectable or advanced disease and relatively preserved daily functioning. They had not received systemic treatment for advanced disease, or previous HER2-targeted drugs or checkpoint inhibitors.
Alex: And what counted as success? Tumor shrinkage can be useful, but it is not the same as extending life.
Sam: The two primary outcomes were progression-free survival and overall survival. Progression-free survival means time until the cancer worsens or the patient dies. Although treatment was open-label, an independent review team, blinded to treatment assignment, assessed progression from scans.
Alex: That separation matters: patients and clinicians knew the treatment, but the central scan reviewers did not. What did those reviewers find?
Sam: Median progression-free survival was 12.4 months with either zanidatamab regimen, compared with 8.1 months with trastuzumab and chemotherapy. Both comparisons were statistically significant. Alternative analyses using different rules for handling the follow-up data gave consistent results.
Alex: The same median in the two experimental groups could tempt someone to say immunotherapy added nothing. Is that a fair reading?
Sam: No. Equal medians do not establish equal outcomes across the full follow-up period. The stated testing strategy compared each experimental regimen with trastuzumab and chemotherapy. It does not establish the incremental benefit of tislelizumab through a definitive comparison between the experimental groups.
Alex: Then the survival result becomes especially important. Did the combination actually extend life against the comparator?
Sam: Median overall survival was 26.4 months with zanidatamab, tislelizumab, and chemotherapy, compared with 19.2 months with trastuzumab and chemotherapy. That difference met the trial’s prespecified significance criteria. It was observed at the first interim survival analysis.
Alex: What about replacing trastuzumab without adding the immunotherapy? That could matter for patients who cannot receive it.
Sam: Survival was numerically longer with zanidatamab and chemotherapy alone, but that comparison did not meet the prespecified significance criteria. Further survival analyses are planned. For now, the established benefit for that regimen is delayed progression, not a demonstrated extension of life.
Alex: The gains need a toxicity account alongside them. What did patients experience?
Sam: About 83 percent of patients receiving the immunotherapy-containing combination had an adverse event of grade three or higher, meaning severe or worse. That proportion was higher than with trastuzumab and chemotherapy. Serious adverse events and treatment discontinuations were also more frequent.
Alex: Which adverse effect most clearly separated the antibody treatments?
Sam: Severe or worse diarrhea affected about a quarter of patients receiving the immunotherapy-containing combination, compared with about thirteen percent receiving trastuzumab and chemotherapy. Diarrhea was also more frequent with zanidatamab without tislelizumab. It generally began early in treatment.
Alex: Was this observed without preventive treatment, or did it happen despite precautions?
Sam: The zanidatamab groups received mandatory diarrhea prevention during the first treatment cycle, plus medication to prevent infusion reactions. The authors suggest those precautions reduced high-grade diarrhea relative to earlier trials. Adding tislelizumab also introduced immune-mediated adverse events, mostly mild or moderate.
Alex: Now the main limitation: a contemporary regimen can include pembrolizumab. Why was that not the comparator?
Sam: The trial was designed before the relevant pembrolizumab results were reported. Trastuzumab plus chemotherapy reflected standard care at that time. The study therefore cannot tell us whether this new combination is superior to trastuzumab, pembrolizumab, and chemotherapy.
Alex: The authors report survival results consistent across immune-marker subgroups. Could that close the gap indirectly?
Sam: It cannot. The marker was programmed death ligand one, or PD-L1, a protein used to characterize immune-checkpoint signaling. Those subgroup analyses were exploratory and underpowered, with no definitive subgroup conclusions justified. They also cannot substitute for a missing treatment comparison.
Alex: So who should read the full document, and where should they begin?
Sam: Researchers in gastrointestinal oncology, HER2-targeted therapy, or antibody–immunotherapy combinations should read it closely. Start with the Efficacy section, separating progression from survival and the two experimental comparisons. Then read Safety, and the Discussion’s account of the outdated comparator and remaining survival follow-up.
Alex: And for a researcher outside those areas, what is the line to remember?
Sam: This trial found better disease control with both new antibody regimens, and longer survival with the immunotherapy-containing combination. But beating the tested treatment does not establish superiority over today’s immunotherapy-containing alternative.
Alex: Keep that comparison in mind when you read the claim.